Unknown

From: Kwang Kon Koh [kwangk@ghil.com]
Sent: Monday, April 23, 2001 8:39 PM
To: Karen Mittleman, PhD
Subject: Re: Final Draft

vcard.vcf (547 B)

Dear Karen:

Thank you for your email.

As I mentioned in my previous email, I had waited for your reply.
I have no idea regarding no reply.

I already mailed out to Circulation last week.
The format for Circulation that you mentioned is right.
However, do not worry about the current format of a review paper.
In general, journals including Circulation do not turn down only by the reason of the format. The important thing is the content, not format. That means you do not need to format again.
If Circulation is willing to accept, it will require to rewrite a manuscript according to the prerequisite format. Just wait for the response of Circulation.
Furthermore, Circulation is one of tough journals and so it is not easy to be accepted.

Now I understand your content and so I will acknowledge your name as your way.

Let's our fingers to be crossed.

Hope to see you in Bermuda.

With best regards,

Dr. Koh

Karen Mittleman, PhD 작성함:

> Dear Dr. Koh:
>
> In looking at the information to authors for Circulation, they request
> that the manuscript that you are submitting has no more than 35
> references and contain no more than 4500 words. At the moment, there
> are 59 references in the paper and it contains 5600 words. In
> addition, the journal requests and abstract (250 words) and a condensed abstract (100 words).
>
> If you would like, we will try to cut down the words and references
> and create the abstracts as requested by the journal. If you have any
> recommendations on sections that could be shortened or deleted, please
> let me know.
>
> Thank you.
>
> Karen
>
> Karen D. Mittleman, Ph.D.
> Senior Medical Writer
> DesignWrite Enterprises, LLC

DESIGN175720

> 189 Wall St.
> Princeton, NJ 08540
> Tel: (609) 524-2315
> Fax: (609) 497-2304
>
> -----Original Message-----
> From: Kwang Kon Koh [mailto:kwangk@ghil.com]
> Sent: Saturday, April 21, 2001 4:27 AM
> To: Karen Mittleman
> Subject: RE: Final Draft
>
> To: Karen Mittleman
> Fax: 001-1-609-497-2304
> Page: one page
>
> Dear Karen:
>
> Did you received my email and fax regarding draft of review paper and
> my
>
> Itinerary?
>
> First of all, I apologize you not to keep my date.
> Please accept my apology. As a matter of fact, I imagined to go over
> quickly.
> However, I figured out review is not simple after all.
> While you look over, you will realize.
>
> When I revised a draft, I invited you and Dr. Cannon as co-authors.
> In the first draft which I sent you by email, I put your name as a
> co-author.
> Dr. Cannon is a well-known expert in this field and very nice gentleman.
>
> I had waited for your reply, but there was no reply.
>
> Meantime, I received a reply from Dr. Cannon.
> Dr. Cannon very kindly gave his comments in my revised draft, however,
> unfortunately he strongly argued a co-authorship.
> For your information, I attach his comments.
> Therefore, it seemed to me there is no way to take off your name and Dr.
> Cannon.
>
> On April 19, Thursday, I mailed out to Circulation.
> I am not sure Circulation will accept, but it may be possible.
>
> If you want your name to be acknowledged, I am willing to.
> Please show me your intent ASAP.
>
> Thanks.
>
> With personal regards,
>
> Kwang Kon Koh, M.D., F.A.C.C.
> Associate Professor
> Director, Vascular Medicine and Atherosclerosis Unit Division of
> Cardiology, Gil Heart Center Gachon Medical School
> 1198 Kuwol-Dong, Namdong-Gu
> Inchon, Korea 405-760
> Tel: 82-32-460-3683
> Fax: 82-32-460-3117
> Email: kwangk@ghil.com
>
> Kwang,
>
> Thanks for letting me read your manuscript. Who is Karen Mittleman?

DESIGN175721

> Does
>
> her company assist in the preparation of manuscripts for authors for
> whom English is not their native language? If so, does this merit
> co-authorship?
>
> The manuscript certainly reads well, and is comprehensive. I have just
> a
>
> few comments:
>
> 1) Page 2, paragraph 3- I suggest " The sharp contrast between the
> above
>
> mentioned observational data and..."
>
> 2) At the bottom of that paragraph, you state that "What has provoked
> concern is the fact that more women in the hormone-treated group
> experienced deep venous thrombosis..." I believe that greater concern
> was (and continues to be) the increased cardiovascular event rate
> (primarily
>
> MI) noted during the first year of hormone therapy.
>
> 3) In the last sentence of page 8, you indicate reference 21, but the
> sentence pertains only to the study of reference 22.
>
> 4) On page 14, you may wish to mention the WISDOM trial in Europe of
> women at high risk for CAD. Should you also mention trials of
> SERMs(RUTH)?
>
> Thanks for offering co-authorship and acknowledgement, but this is
> your work, and you should receive all credit. That's why I raise the
> issue of
>
> including Karen Mittleman as a co-author.
>
> Best wishes,
>
> Richard
>
> -----Original Message-----
> From: Kwang Kon Koh [mailto:kwangk@ghil.com]
> Sent: Monday, April 16, 2001 8:43 AM
> To: Cannon, Richard (NHLBI)
> Subject: RE: Invitation to Co-authors
>
> Richard,
>
> As you may be aware, hormone replacement therapy is not simple.
> Recently, I and Karen wrote a new review paper focused on healthy
> endothelium.
> May I ask you to go over this one and give me comments?
>
> I would like to invite you to co-authors, not being acknowledged.
> As I talked to you in Orlando, I would be very happy if you accept my
> sincere invitation to co-authors.
>
> Here is in mood of spring blossoms.
> I guess cherry blossom blooms in Washington now.
>
> Many thanks for your comments all times.
>
> In friendship,
>

DESIGN175722

> Kwang-kon

DESIGN175723